argenx Beheer

Beheer criteriumcontroles 2/4

De CEO argenx is Tim Van Hauwermeiren, benoemd in Apr2008, heeft een ambtstermijn van 16.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.94M, bestaande uit 5.5% salaris en 94.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.023% van de aandelen van het bedrijf, ter waarde € 7.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 7.5 jaar.

Belangrijke informatie

Tim Van Hauwermeiren

Algemeen directeur

US$11.9m

Totale compensatie

Percentage CEO-salaris	5.5%
Dienstverband CEO	16.5yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Tim Van Hauwermeiren's beloning veranderd ten opzichte van argenx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$328m
Dec 31 2023	US$12m	US$656k	-US$295m
Sep 30 2023	n/a	n/a	-US$234m
Jun 30 2023	n/a	n/a	-US$397m
Mar 31 2023	n/a	n/a	-US$511m
Dec 31 2022	US$8m	US$639k	-US$710m
Sep 30 2022	n/a	n/a	-US$909m
Jun 30 2022	n/a	n/a	-US$907m
Mar 31 2022	n/a	n/a	-US$595m
Dec 31 2021	US$7m	US$652k	-US$408m
Sep 30 2021	n/a	n/a	-US$373m
Jun 30 2021	n/a	n/a	-US$319m
Mar 31 2021	n/a	n/a	-US$573m
Dec 31 2020	US$9m	US$641k	-US$608m
Sep 30 2020	n/a	n/a	-US$535m
Jun 30 2020	n/a	n/a	-US$359m
Mar 31 2020	n/a	n/a	-US$275m
Dec 31 2019	US$7m	US$589k	-US$181m
Sep 30 2019	n/a	n/a	-US$109m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$47m
Dec 31 2018	US$5m	US$573k	-US$76m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$46m
Dec 31 2017	US$4m	US$365k	-US$34m

Compensatie versus markt: De totale vergoeding ($USD 11.94M ) Tim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Austrian markt ($USD 4.34M ).

Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tim Van Hauwermeiren (52 yo)

16.5yrs

Tenure

US$11,944,835

Compensatie

Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, serves as Independent Non-Executive Director of Lexeo Therapeutics, Inc since July 2024. He has been Independent Director at iTeos Therapeutics,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Van Hauwermeiren	CEO & Executive Director	16.5yrs	US$11.94m	0.023% € 7.2m
Karl Gubitz	Chief Financial Officer	3.3yrs	US$4.76m	0.0050% € 1.5m
Karen Massey	Chief Operating Officer	1.6yrs	US$7.65m	geen gegevens
Filip Borgions	VP & Global Head of Technical Operations	2.5yrs	geen gegevens	geen gegevens
Peter Ulrichts	Chief Scientific Officer	1.8yrs	geen gegevens	0.00086% € 263.1k
Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations	2.5yrs	geen gegevens	geen gegevens
Malini Moorthy	General Counsel	2.7yrs	geen gegevens	0% € 0
Arjen Lemmen	Vice President of Corporate Development & Strategy	5.3yrs	geen gegevens	0.0021% € 627.1k
Marc Schorpion	Global Head of Human Resources	5.8yrs	geen gegevens	geen gegevens
Andria Wilk	Global Head of Quality	4.8yrs	geen gegevens	0.00050% € 153.0k
Luc Truyen	Chief Medical Officer	2.5yrs	geen gegevens	0.0027% € 835.2k

2.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Van Hauwermeiren	CEO & Executive Director	10.3yrs	US$11.94m	0.023% € 7.2m
J. deBethizy	Independent Vice-Chairman of the Board	9.4yrs	US$482.23k	0.00065% € 198.8k
Peter K. Verhaeghe	Independent Chairman of the Board	10.3yrs	US$660.33k	0.0023% € 709.7k
Anthony Rosenberg	Independent Non-Executive Director	7.5yrs	US$476.82k	0.00065% € 198.8k
James Daly	Independent Non-Executive Director	6.4yrs	US$482.23k	0.00065% € 198.8k
Pamela M. Klein	Independent Non-Executive Director	8.5yrs	US$471.41k	0.00065% € 198.8k
Hans de Haard	Member of Board Advisors	no data	geen gegevens	0.62% € 189.1m
David Lacey	Member of Board Advisors	no data	US$622.58k	geen gegevens
Steve Krognes	Independent Non-Executive Director	1.7yrs	US$635.65k	0.00022% € 67.3k
Camilla Sylvest	Independent Non-Executive Director	2.1yrs	US$365.24k	0.00086% € 263.1k
Robert Woods	Member of Board Advisors	1.6yrs	US$656.08k	0.0055% € 1.7m
Wim Parys	Member of Board Advisors	no data	geen gegevens	geen gegevens

7.5yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

argenx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Independent Non-Executive Director recently sold €1.9m worth of stock

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

Independent Chairman of the Board recently sold €3.8m worth of stock

CEO & Executive Director recently sold €1.9m worth of stock

Recent updates

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Independent Non-Executive Director recently sold €1.9m worth of stock

Second quarter 2024 earnings released: EPS: US$0.49 (vs US$1.69 loss in 2Q 2023)

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Full year 2023 earnings released: US$5.16 loss per share (vs US$13.05 loss in FY 2022)

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

New major risk - Share price stability

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings released: US$1.25 loss per share (vs US$4.26 loss in 3Q 2022)

Forecast to breakeven in 2025

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director recently sold €1.9m worth of stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$1.69 loss per share (vs US$3.81 loss in 2Q 2022)

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Now 20% undervalued

First quarter 2023 earnings released: US$0.52 loss per share (vs US$4.36 loss in 1Q 2022)

First quarter 2023 earnings released: US$0.52 loss per share (vs US$4.36 loss in 1Q 2022)

CEO & Executive Director recently sold €118k worth of stock

Full year 2022 earnings released: US$13.05 loss per share (vs US$7.99 loss in FY 2021)

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

Forecast to breakeven in 2025

Forecast to breakeven in 2025

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

Insufficient new directors

Independent Non-Executive Director recently sold €960k worth of stock

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

Third quarter 2022 earnings released: US$4.26 loss per share (vs US$4.10 loss in 3Q 2021)

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

Second quarter 2022 earnings released: US$3.81 loss per share (vs US$2.02 profit in 2Q 2021)

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

First quarter 2022 earnings released: US$4.36 loss per share (vs US$0.81 loss in 1Q 2021)

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Insufficient new directors

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

Independent Non-Executive Director recently sold €2.3m worth of stock

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Third quarter 2021 earnings released: US$4.10 loss per share (vs US$3.92 loss in 3Q 2020)